• Dupixent improves itch, hives in phase 3 chronic spontaneous urticaria trial

    1 month ago - By Healio

    Dupixent reduced both itch and hives in patients with moderate to severe chronic spontaneous urticaria in a pivotal phase 3 trial, Regeneron and Sanofi announced in a press release.
    Dupixent met all of the primary and key secondary endpoints at 24-weeks in a trial of 138 biologic-naive patients. Patients received either standard-of-care antihistamines plus Dupixent or antihistamines alone.
    Itch severity was reduced 63% in the Dupixent group compared with 35% in the placebo group (P
    Read more ...